| 孙成芝,汪发莲,杨君慧,张 蕾,潘雪萍.α-硫辛酸联合依帕司他对糖尿病周围神经病变患者血糖、神经传导速度及血清炎症因子的影响[J].现代生物医学进展英文版,2020,(20):3947-3950. |
| α-硫辛酸联合依帕司他对糖尿病周围神经病变患者血糖、神经传导速度及血清炎症因子的影响 |
| Effects of α-lipoic Acid Combined with Epalrestat on Blood Glucose, Nerve Conduction Velocity and Serum Inflammatory Factors in Diabetic Peripheral Neuropathy |
| Received:April 10, 2020 Revised:April 30, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.20.032 |
| 中文关键词: α-硫辛酸 依帕司他 糖尿病周围神经病变 血糖 神经传导速度 炎症因子 |
| 英文关键词: α-lipoic acid Epalrestat Diabetic peripheral neuropathy Blood glucose Nerve conduction velocity Inflammatory factors |
| 基金项目:青海省科技厅计划项目（9631011Y0225） |
|
| Hits: 750 |
| Download times: 438 |
| 中文摘要: |
| 摘要 目的：探讨α-硫辛酸联合依帕司他对糖尿病周围神经病变（DPN）患者血糖、神经传导速度及血清炎症因子的影响。方法：选取2016年7月~2019年12月期间我院收治的DPN患者460例，按随机数字表法将上述患者分为对照组（n=230）和研究组（n=230），对照组患者予以依帕司他治疗，研究组则在对照组的基础上联合α-硫辛酸治疗，比较两组患者疗效、血糖、神经传导速度、血清炎症因子及不良反应。结果：研究组治疗2个月后的临床总有效率为86.09%（198/230），高于对照组的69.13%（159/230）（P<0.05）。两组治疗2个月后空腹血糖（FPG）、餐后2 h血糖（2hPG）均下降，且研究组低于对照组（P<0.05）。两组治疗2个月后正中神经运动神经传导速度 ( MCV) 和感觉神经传导速度( SCV)及腓总神经MCV、SCV均升高，且研究组高于对照组（P<0.05）。两组治疗2个月后白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、超敏-C反应蛋白（hs-CRP）均下降，且研究组低于对照组（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：α-硫辛酸联合依帕司他治疗DPN患者，疗效显著，可有效降低血糖，改善神经传导速度及血清炎症因子水平，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of α-lipoic acid combined with epalrestat on blood glucose, nerve conduction velocity and serum inflammatory factors in patients with diabetic peripheral neuropathy (DPN). Methods: 460 DPN patients who were treated in our hospital from July 2016 to December 2019 were sleected, they were randomly divided into two groups: control group (n=230) and study group (n= 230). Patients in the control group were treated with epalrestat, while patients in the study group were treated with -lipoic acid on the basis of the control group. The efficacy, blood glucose, nerve conduction velocity, serum inflammatory factors and Adverse reactions. Results: The total clinical effective rate of the study group was 86.09% (198/230), which was higher than 69.13% (159/230) of the control group (P<0.05). Fasting blood glucose (FPG), 2 hours postprandial blood glucose (2hPG) in the two groups decreased after 2 months of treatment and the level in the study group was lower than that in the control group (P<0.05). The MCV and SCV of median nerve and common peroneal nerve in the two groups were higher than those in the control group (P<0.05). Interleukin-6 (IL-6), tumor necrosis factor -α(TNF-α), hypersensitive -C reactive protein (hs-CRP) decreased in the two groups after 2 months of treatment and the level in the study group was lower than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: α-lipoic acid combined with epalrestat is effective in the treatment of DPN. It can effectively reduce blood glucose, improve nerve conduction velocity and serum inflammatory factor level, and has good safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
